NASDAQ:AKBA Akebia Therapeutics (AKBA) Stock Price, News & Analysis $1.02 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$1.01 -0.01 (-0.49%) As of 05/22/2026 06:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Akebia Therapeutics Stock (NASDAQ:AKBA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Akebia Therapeutics alerts:Sign Up Key Stats Today's Range$1.00▼$1.0550-Day Range$0.90▼$1.5652-Week Range$0.88▼$4.08Volume2.32 million shsAverage Volume5.40 million shsMarket Capitalization$273.63 millionP/E RatioN/ADividend YieldN/APrice Target$4.67Consensus RatingHold Company Overview Akebia Therapeutics, Inc., a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, is focused on the development and commercialization of therapies for patients with kidney disease. The company’s lead product candidate, vadadustat, is an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor designed to treat anemia associated with chronic kidney disease in both dialysis-dependent and non-dialysis patients. Akebia’s research and development efforts also extend to preclinical programs targeting nephrology and related metabolic disorders. Since its founding in 2007, Akebia has pursued strategic collaborations to advance its clinical pipeline and expand its market reach. The company has partnered with Otsuka Pharmaceutical for filing and commercialization of vadadustat in the United States, while Mitsubishi Tanabe Pharma holds rights to develop and commercialize the compound in ex-Japan territories. These alliances leverage Akebia’s scientific expertise alongside the global commercialization networks of its partners. In addition to its focus on anemia in kidney disease, Akebia evaluates novel mechanisms of action aimed at improving kidney health and patient outcomes. The company maintains clinical trial sites across North America and engages with healthcare providers, academic institutions and patient advocacy groups to support the design and execution of its studies. Under the leadership of President and Chief Executive Officer John P. Butler, Akebia continues to build its development infrastructure and prepare for potential regulatory milestones.AI Generated. May Contain Errors. Read More Akebia Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks49th Percentile Overall ScoreAKBA MarketRank™: Akebia Therapeutics scored higher than 49% of companies evaluated by MarketBeat, and ranked 524th out of 869 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingHold Consensus RatingAkebia Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and 2 sell ratings.Upside PotentialAkebia Therapeutics has a consensus price target of $4.67, representing about 357.5% upside from its current price of $1.02.Amount of Analyst CoverageAkebia Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Akebia Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Akebia Therapeutics are expected to decrease in the coming year, from ($0.03) to ($0.14) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Akebia Therapeutics is -12.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Akebia Therapeutics is -12.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAkebia Therapeutics has a P/B Ratio of 10.20. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Akebia Therapeutics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.76% of the float of Akebia Therapeutics has been sold short.Short Interest Ratio / Days to CoverAkebia Therapeutics has a short interest ratio ("days to cover") of 11.35, which indicates bearish sentiment.Change versus previous monthShort interest in Akebia Therapeutics has recently increased by 1.13%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAkebia Therapeutics does not currently pay a dividend.Dividend GrowthAkebia Therapeutics does not have a long track record of dividend growth. News and Social Media2.7 / 5News SentimentN/A News SentimentAkebia Therapeutics has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Akebia Therapeutics this week, compared to 4 articles on an average week.Search Interest9 people have searched for AKBA on MarketBeat in the last 30 days. This is an increase of 350% compared to the previous 30 days.MarketBeat Follows3 people have added Akebia Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership3.4 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $86,588.00 in company stock, which represents 0.0316% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Akebia Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $86,588.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders4.30% of the stock of Akebia Therapeutics is held by insiders.Percentage Held by Institutions33.92% of the stock of Akebia Therapeutics is held by institutions.Read more about Akebia Therapeutics' insider trading history. Receive AKBA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Akebia Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AKBA Stock News HeadlinesAkebia Therapeutics (NASDAQ:AKBA) Shares Cross Below Two Hundred Day Moving Average - Should You Sell?May 20, 2026 | americanbankingnews.comAkebia Therapeutics (AKBA) Receives a Buy from H.C. WainwrightMay 18, 2026 | theglobeandmail.comNobody Understands Why Trump Is Invading Iran (here’s the answer)Most investors are reacting to the Iran strikes without understanding the underlying motive driving the decision. Addison Wiggin, Founder of Grey Swan Investment Fraternity, says there is a hidden reason behind the bombing - and knowing it could change how you position your money right now.May 25 at 1:00 AM | Banyan Hill Publishing (Ad)Analysts Are Updating Their Akebia Therapeutics, Inc. (NASDAQ:AKBA) Estimates After Its First-Quarter ResultsMay 11, 2026 | finance.yahoo.comAkebia Therapeutics, Inc. (AKBA) Q1 2026 Earnings Call TranscriptMay 7, 2026 | seekingalpha.comAkebia plunges 20% on muted Q1 printMay 7, 2026 | msn.comAkebia Therapeutics Reports First Quarter 2026 Financial Results and Commercial and Pipeline HighlightsMay 7, 2026 | globenewswire.comAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 4, 2026 | globenewswire.comSee More Headlines AKBA Stock Analysis - Frequently Asked Questions How have AKBA shares performed this year? Akebia Therapeutics' stock was trading at $1.61 on January 1st, 2026. Since then, AKBA stock has decreased by 36.6% and is now trading at $1.02. How were Akebia Therapeutics' earnings last quarter? Akebia Therapeutics, Inc. (NASDAQ:AKBA) released its quarterly earnings data on Thursday, May, 7th. The biopharmaceutical company reported ($0.03) EPS for the quarter, missing the consensus estimate of ($0.01) by $0.02. The biopharmaceutical company had revenue of $53.54 million for the quarter, compared to the consensus estimate of $51.67 million. Akebia Therapeutics had a negative trailing twelve-month return on equity of 62.72% and a negative net margin of 8.83%. Read the conference call transcript. When did Akebia Therapeutics IPO? Akebia Therapeutics (AKBA) raised $91 million in an IPO on Thursday, March 20th 2014. The company issued 5,882,353 shares at $14.00-$17.00 per share. Who are Akebia Therapeutics' major shareholders? Top institutional shareholders of Akebia Therapeutics include Bank of America Corp DE (1.03%), Renaissance Technologies LLC (0.68%), Dimensional Fund Advisors LP (0.34%) and Bank of New York Mellon Corp (0.24%). Insiders that own company stock include John P Butler, Steven Keith Burke, Michel Dahan, Nicole R Hadas, Erik Ostrowski, Nicholas Grund and Richard C Malabre. View institutional ownership trends. How do I buy shares of Akebia Therapeutics? Shares of AKBA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Akebia Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Akebia Therapeutics investors own include Novavax (NVAX), NVIDIA (NVDA), Tesla (TSLA), Meta Platforms (META), Advanced Micro Devices (AMD), Intel (INTC) and ExxonMobil (XOM). Company Calendar Last Earnings5/07/2026Today5/25/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (4m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 AKBA's financial health is in the Red zone, according to TradeSmith. AKBA has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AKBA CIK1517022 Webwww.akebia.com Phone(617) 871-2098Fax617-871-2099Employees430Year Founded2007Price Target and Rating Average Price Target for Akebia Therapeutics$4.67 High Price Target$6.00 Low Price Target$4.00 Potential Upside/Downside+357.5%Consensus RatingHold Rating Score (0-4)2.20 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($0.08) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$5.34 million Net Margins-8.83% Pretax Margin-8.07% Return on Equity-62.72% Return on Assets-5.66% Debt Debt-to-Equity Ratio1.33 Current Ratio1.40 Quick Ratio1.33 Sales & Book Value Annual Sales$236.20 million Price / Sales1.16 Cash FlowN/A Price / Cash FlowN/A Book Value$0.10 per share Price / Book10.20Miscellaneous Outstanding Shares268,260,000Free Float256,723,000Market Cap$273.63 million OptionableOptionable Beta0.35 Social Links 5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:AKBA) was last updated on 5/25/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akebia Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Akebia Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
